Aaron Sulkes MD, Daniel Reinhorn MD, Tzeela Cohen MD, Tatiana Peysakhovich MD, Victoria Neiman MD, Baruch Brenner MD
Docetaxel (Taxotere®), obtained from the European yew Taxus baccata, is a widely used chemotherapeutic agent active against a variety of solid tumors including breast, lung, ovarian, gastric, head and neck, and prostate cancers. The drug is administered intravenously on a weekly or three-weekly schedule. Its main side effects include myelosuppression, fatigue, myalgias, arthralgias, fluid retention, peripheral neuropathy, paronychia, and lacrimation [1]. Myositis, however, has rarely been reported.
We describe a breast cancer patient who developed severe acute myositis while on treatment with docetaxel.